MedTrace Logo

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

NCT05193578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2024-07-08

No results posted yet for this study

Summary

To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and schizophrenia, who receive antipsychotic treatment.

Furthermore to investigate for an effect of Semaglutide compared to placebo on psychotic symptoms and quality of life in people with schizophrenia, prediabetes and overweight.

Conditions

Interventions

DRUG

Semaglutide, 1.34 mg/mL

Semaglutide, 1.34 mg/mL

OTHER

Placebo

Semaglutide-Placebo

Sponsors & Collaborators

  • Region Zealand

    collaborator OTHER

  • Region of Southern Denmark

    collaborator OTHER

  • Steno Diabetes Center Sjaelland

    collaborator OTHER_GOV

  • Steno Diabetes Center Odense

    collaborator OTHER

  • Jan Frystyk

    lead OTHER

Principal Investigators

  • Jan Frystyk, Professor · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-03-18
Completion
2024-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193578 on ClinicalTrials.gov